Alterity Therapeutics Limited (ASX:ATH)


right-arrow Created with Sketch. -0.001 (-4.17%)
MCAP $55.35M
Last trade 16.10pm 03/12/2021 20mins delayed

Latest Announcements

24/11/2021ATHAlterity Therapeutics Limited
22/11/2021ATHAlterity Therapeutics Limited
12/11/2021ATHAlterity Therapeutics Limited
12/11/2021 Price SensitivePSATHAlterity Therapeutics Limited
12/11/2021 Price SensitivePSATHAlterity Therapeutics Limited
09/11/2021ATHAlterity Therapeutics Limited
04/11/2021 Price SensitivePSATHAlterity Therapeutics Limited
03/11/2021ATHAlterity Therapeutics Limited

Company Overview

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.

ATH in the news

Alterity Therapeutics (ATH) expands its clinical development program for lead asset ATH343…
The findings of a study by Alterity Therapeutics (ATH) demonstrate its ATH434…
Alterity Therapeutics (ATH) says it has secured a “broad monopoly” over a…
Alterity Therapeutics (ATH) will present new findings of its ATH434 drug’s ability…

Search Previous Announcements